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ABSTRACT  
Over the past 4 and 1/2 years, a total of 97 patients had hypertension yet lacked clinical, laboratory and radiological evide nce of renal, 
renovascular and endocrine disease were investigated for A/R ratio.  High A/R was detected in 30 patients.  Five patients had unilateral adrenal 
adenoma and 1 had cancer while 24 patients (24.7%) had bilateral enlargements indicating bilateral adrenal hyperplasia (BAH).   Our study has 
shown that BAH is: (a) easily diagnosed with a combination of A/R ratio and CT scan of the adrenal gland, (b) responsible for 24.7% of 
hypertension cases, (c) associated with moderate to severe hypertension that may require 2-4 antihypertensives, (d) associated with 
hypokalemia in only in 54% of the cases, (e) not controlled with a single daily dose of Spironolactone (S) and ½ the cases require 50 mg/day.   
Moreover, it has shown that S treatment was not associated with significant hyperkalemia yet gynecomastia and erectile dysfunction were 
common side effects.  Interestingly; and despite normalization of A/R ratio, most patients continue to require antihypertensive drugs thoug h 
the number and dosage were less.  The latter phenomenon was more evident in those with higher initial A/R ratio and longer duration of 
hypertension.  Nephroangiosclerosis is the most plausible explanation for it.  In conclusion; BAH is not a rare disease and should be considered 
in cases of refractory hypertension.   
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INTRODUCTION 
Primary hyperaldosteronism (PH) refers to overproduction 
of aldosterone.  It used to be an under-recognized cause of 
hypertension yet in recent studies it has reached a 
prevalence of 10% in hypertensive patients [1].  It can be 
associated with bilateral adrenal hyperplasia (BAH) in 66% 
of cases, adrenal adenoma in 33%, unilateral adrenal 
hyperplasia in 2%, aldosterone-producing adrenocortical 
carcinoma in <1%, familial hyperaldosteronism in <2% and 
ectopic aldosterone-producing adenoma or carcinoma in < 
0.1% of cases [2].  On the other hand, secondary 
hyperaldosteronism is derived from an elevated renin 
associated with renal hypoperfusion due to intravascular 
volume contraction, poor perfusion pressure, renovascular 
disorders and parenchymal kidney disease [3].  While the 
treatment of secondary hyperaldosteronism is directed to 
the underlying cause; treatment of BAH is by aldosterone-
antagonists [4].  Spironolactone acts primarily on the 
principal cells of the distal convoluted tubules and 
medullary collecting ducts leading to activation of sodium-
potassium ATPase.  Hence it leads to sodium and water 
reabsorption and potassium secretion [5].  Initial attempts 
to limit diagnosis of PH to “hypertension with hypokalemia 
and alkalosis” and laboratory diagnosis with high serum or 
24-hour urine aldosterone lead to under-estimation of the 
prevalence of the disorder.  Subsequently, most of those 
cases were misdiagnosed and were categorized as “essential 
hypertension” [4].  Recently, high aldosterone/renin ratio 
(A/R ratio) has been proposed as a better marker for PH 
compared to the previous tests since they are affected by 
age, sex, posture, hydration state, sodium-intake, storage 
conditions, medications (antihypertensives, diuretics and 
contraceptives) and renal function.  Such marker for PH led 
to improvement in diagnosis of its subclinical states and 
their prevalence [6].  In the current study; we present our 
experience BAH in our area and its management. 
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PATIENTS AND METHODS: 
Study design: 
Patients with hypertension who attended Dr. El-Reshaid 
kidney clinic from 1st January 2014 to 31st June 2019 were 
analyzed prospectively for BAH.  The clinic was established 
in 1997 in the center of Kuwait city.  It is a referral center 
and with adequate diagnostic as well as therapeutic facilities 
to care for both in- and out-patients with all medical and 
renal diseases.      
Inclusion criteria: 
Patients were included, in the study, if they had BAH.  The 
latter was defined as hypertension with diastolic blood 
pressure above 90 mm Hg and associated with: (a) high A/R 
ratio, males: 10.2-23.7 and females: 15.7-41.9 [7],  (b) 
normal or bilaterally enlarged adrenal glands without 
masses by computerized axial tomography (CAT) scanning, 
(c) normal capoten-renogram, and (d) normal DMSA nuclear 
scan.  Aldosterone antagonists were discontinued 3 weeks 
prior to evaluation with A/R ratio. 
Exclusion criteria: 
1- High serum free thyroxin, catecholamines, and cortisol. 
2- Patients with acromegaly (clinical features and positive 
oral glucose tolerance test) 
3- Patients with creatinine clearance < 60 ml/minute. 
4- Patients with volume depletion, decrease effective 
intravascular volume i.e. heart failure, nephrotic 
syndrome or liver disease.   
Initial assessment: 
Patients with hypertension and high A/R ratio had detailed 
laboratory and radiological testing to satisfy inclusion 
criteria.  The laboratory ones included: (a) serum urea, 
creatinine and 24 hour urine collection for creatinine 
clearance and protein output, (b) serum electrolytes viz. 
sodium, potassium and bicarbonate content, uric acid (c) 
urine routine and microscopy, (c) ultrasound of the 
abdomen for liver, spleen, kidneys sizes and abnormality as 
well as the presence of ascites, (d) echocardiogram to assess 
for pericardial, valvular disease and LVEF, (e) capoten 
renogram to assess for renovascular disease, (f) DMSA 
nuclear scan to rule out renal scars, and finally (g) CT scan of 
the adrenal glands to ensure normal adrenals or bilateral 
hyperplasia.   
Introduction of Spironolactone (S): 
The drug was started twice/weekly and the dose was 
increased further to thrice/weekly by week 2 then 
once/daily by week 3 if no hypokalemia.  The dosage of anti-
hypertensive drugs was reduced or omitted if blood 
pressure drops.   The dose of S was increased after 1 month 
if A/R ratio remained above normal range and blood 
pressure as well as potassium level permits.   
Follow up testing:  
Included; clinical and serum testing for renal function and 
electrolytes every 2 weeks.   A/R ratio was done after 1 and 
2 month of follow up.   
Statistical analysis: 
SPSS statistical package version 25 was used for data entry 
and processing.  The p-value <0.05 was used as the cut-off 
level for significance.  Mean and standard deviation were 
used to describe the normally distributed variables viz. age, 
duration of hypertension.  Since A/R ratio, duration of follow 
up while on S therapy and number of antihypertensive drugs 
used before and after starting S were not normally 
distributed; they were expressed as median (interquartile 
range).  Moreover, comparison of changes in A/R ratio at 
different times (0, 1 and 2 months) was done using Wilcoxon 
Signed rank test while student t-test was used to compare 
age and duration of hypertension between males and 
females. 
RESULTS 
Demographical data: 
Over the past 4 and 1/2 years, a total of 97 patients had 
hypertension yet lacked clinical, laboratory and radiological 
evidence of renal, renovascular and endocrine disease were 
investigated for A/R ratio.  High A/R was detected in 30 
patients.  Five patients had unilateral adrenal adenoma and 
1 had cancer while 24 patients (24.7%) had bilateral 
enlargements.  The latter group of patients has satisfied the 
criteria of BAH and hence they were included in the study.  
Their demographical data and results of their tests on follow 
up are shown in table 1 and summery of the statistical 
analysis is summarized in table 2.  Females constituted 
14/24 (58%) and had a mean age (+SD) of 36.7+9 while the 
latter was 35.8+6 in males.  The median (IQ) duration of 
hypertension was 3 (4) years in females while it was 4 (3) in 
males.  Both parameters (age and duration of hypertension) 
were statistically similar between sexes.  Hypokalemia was 
detected only in 13 patients (54%).     
Patients’ characteristics: 
Patients with high A/R ratio had moderate to severe 
hypertension.  To achieve acceptable level of normotension, 
2 patients had required a combination of 4 different groups 
of drugs and 16 had required 3 drugs.  None had required a 
single drug-therapy.    
Efficacy of S: 
1- With 25 mg daily, all patients had improvement in 
their hypertension and A/R.  However, by 1 month, 
only 12 patients had achieved normal A/R ratio.  Their 
A/R ratio did not change significantly by the end of the 
second month.  The 12 patients, who did not achieve 
normal levels of A/R ratio, by the first month, had 
further improvement with 50 mg daily.  However, 2 
patients (n: 7 & 21) had mildly elevated A/R ratio 1 
month after increment of S to 50 mg/day.   
2- Overall, blood pressure was well controlled and with 
less medications after starting S (p= <0.002).  However, 
and despite normalization of A/R ratio; 18 patients 
(75%) were still requiring antihypertensive drugs. In 
the latter patients, the drug-combinations were < 2. 
Moreover, higher the number of initial and final drug 
therapy were associated with longer duration of 
hypertension prior to inclusion in the study and vice 
versa.   
Side effects of S: 
In general the drug was well tolerated except for 4 patients 
with severe gynecomastia and 3 with erectile dysfunction.  
By the first month, none of the patients had hypokalemia.  
With S treatment and diet, none of the patients had 
significant hyperkalemia that indicated discontinuation of S 
therapy. 
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Table 1.  Demographical data on the patients with adrenal hyperplasia and their response to Spironolactone 
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Abbreviations: BP: hypertension, F: female, M: males, Y: present, N: absent, Aldo/R ratio: Aldosterone/Renin ration 
  * Reference range for M: 10.2-23.7 & F: 15.7-41.9 
 
Table 2. Summery of the statistical analysis of the results of the study 
 Parameter 
  
Total 
 
Males   Females   P-value 
 
   
(n: 24) 
 
(n: 10) 
 
(n: 14) 
                     
 
Age: 
  
36+8 
 
36+6 
 
37+9 
 
NS 
 
Duration of hypertension: 3 (3), (1-7) 
 
4 (3), (1-6) 
 
3(4), (1-7) 
 
NS 
 
Aldosterone/Renin ratio: 
        
 
Time 0: 
   
98 (45) 
 
101(58) 
   
 
Time 1 month: 
  
43(29) 
 
41(24) 
   
 
Time 2 months 
  
21(6) 
 
38(9) 
   
 
P-value 
   
0.002 
 
0.001 
   
Duration of follow up: 6(3), (2-6) 
 
6(3), (2-6) 
 
5.5(3), (2-6) 
 
NS 
 
Number of BP drugs: 
        
 
Initial: 
 
3(0) 
 
3(0) 
 
3(1) 
   
 
Final: 
 
1(0) 
 
1(0) 
 
1(1) 
   
 
P-value 
   
0.002 
 
0.002 
   
Hypokalemia: 
 
13/24(54%) 
 
6/10(60%) 
 
7/14(50) 
   
50 mg requirement: 
 
12/24(60%) 
 
7/10(70%) 
 
5/14(38%) 
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DISCUSSION 
Hypertension is a major risk factor for coronary artery 
disease, stroke, heart failure, atrial fibrillation, peripheral 
arterial disease, vision loss, chronic kidney disease, 
and dementia [8].  
It has been classified as either primary 
(essential) or secondary hypertension.  Nearly 95% of cases 
are considered primary and has been attributed to 
nonspecific lifestyle and genetic factors.  The remaining 5% 
of secondary cases were attributed to chronic kidney disease, 
narrowing of the kidney arteries, an endocrine disorder, or 
the use of birth control pills [9].  Kidney disease was 
considered the most common secondary cause of 
hypertension while endocrine ones viz. Cushing’s syndrome, 
hyperthyroidism, acromegaly, hyperaldosteronism, and 
pheochromocytoma [10].  Our study has shown that BAH is: 
(a) can be easily diagnosed with a combination of A/R ratio 
and CT scan of the adrenal gland, (b) responsible for 24.7% 
of hypertension cases, (c) associated with moderate to 
severe hypertension that may require 2-4 antihypertensives, 
(d) associated with hypokalemia in only in 54% of the cases, 
(e) not controlled with a single daily dose of S and ½ the 
cases require 50 mg/day.   Moreover, it has shown that S 
treatment was not associated with significant hyperkalemia 
yet gynecomastia and erectile dysfunction were common 
side effects.  Fortunately, in 1983, a selective aldosterone 
receptor antagonist (SARA) was approved for medical use in 
USA [11].  The latter has similar diuretic effect of S yet 
without its antiandrogenic effect.  It is relatively costly and 
hence can be reserved for patients with significant side 
effects following S therapy.  Interestingly; and despite 
normalization of A/R ratio, most patients continue to require 
antihypertensive drugs.  Since the drug-combination was less 
in those with shorter duration of hypertension prior to 
inclusion and higher in those with long-history of disease; its 
pathogenesis is related to Nephroangiosclerosis.  The latter 
includes permanent damage to the arterioles 
(arteriosclerosis) that leads to tubular atrophy, interstitial 
fibrosis and glomerular ischemia [12].].  Hence, and 
theoretically, ACEI and ARB are the drugs of choice following 
S treatment of BAH.  Unfortunately, hyperkalemia can be a 
major limiting factor for such drug combination.  Ultimately, 
the management plan should be individualized based on the 
condition of the patient including his co-morbid conditions, 
stage of hypertension and his kidneys.  In conclusion; BAH is 
not a rare disease and should be considered in cases of 
refractory hypertension.  Treatment with S can normalize 
A/R ratio and lower the drug-requirements but not for those 
long-standing hypertension.  
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